357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial.
Saved in:
| Title: | 357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial. |
|---|---|
| Authors: | Goetze, T.O.1 (AUTHOR), Vogel, A.2 (AUTHOR), Gonzalez Carmona, M.A.3 (AUTHOR), Habibzade, T.4 (AUTHOR), Reinecke, J.5 (AUTHOR), Adler, M.6 (AUTHOR), Pink, D.7 (AUTHOR), Ettrich, T.J.8 (AUTHOR), Roderburg, C.9 (AUTHOR), Pession, U.10 (AUTHOR), Saborowski, A.2 (AUTHOR), Van Bömmel, F.11 (AUTHOR), Wehler, T.C.12 (AUTHOR), Koehne, C-H.13 (AUTHOR), Schaaf, M.14 (AUTHOR), Sookthai, D.14 (AUTHOR), Eickhoff, R.14 (AUTHOR), Pons, M.14 (AUTHOR), Al-Batran, S-E.1 (AUTHOR), Modest, D.P.15 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 1, Vol. 36, pS140-S140. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
